author-photo

Andrea Pellacani

University of Bologna

56

Papers

358

Citations

Citation Trend

Filter By

Papers (38) Sort By

Journal Conference Others

266P MEN1611, a PI3K inhibitor, combined with trastuzumab (T) ± fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC): Safety and efficacy results from the ongoing phase Ib study (B-PRECISE-01)

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
489P MEN1611 in combination with cetuximab: Targeting PIK3CA mutations in RAS-wild-type patient-derived colorectal cancer xenografts

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Abstract PS18-13: Men1611 is a pi3k α/β selective and δ sparing inhibitor with long-lasting antitumor activity in different genetic backgrounds of pik3ca mutant breast cancer models

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 1170: MEN1112/OBT357, a first-in-class humanized de-fucosylated monoclonal antibody targeting CD157 positive cells in acute myeloid leukemia and myelodysplastic syndrome

2021
Show All
- Source
- Cite
- Save
Citations (0)
P-79 C-PRECISE-01 study: A phase Ib/II trial of MEN1611, a PI3K inhibitor, and cetuximab in patients with PIK3CA mutated metastatic colorectal cancer failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimens

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models.

2020 Haematologica
Show All
- Source
- Cite
- Save
Citations (10)
SEL24/MEN1703 Provides PIM/FLT3 Downstream Pathway Inhibition in Acute Myeloid Leukemia (AML) Blast Cells: Results of the Pharmacodynamics (PD) Assay in the Dose Escalation Part of First-in-Human Diamond Trial

2020 Blood
Show All
- Source
- Cite
- Save
Citations (0)
B-PRECISE-01 Study: A phase Ib trial of MEN1611, a PI3K Inhibitor, combined with trastuzumab ± fulvestrant for the treatment of HER2-positive advanced or metastatic breast cancer.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
1938PCharacterization of the mechanism of action and efficacy of MEN1611 (PA799), a novel PI3K inhibitor, in breast cancer preclinical models

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (2)